Clinical Trial

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

Study acronym: PSMA SRT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after surgery. 68Ga-PSMA-11 are taken up by cancer cells. Diagnostic procedures, such as PET/CT scans, may help find and diagnose prostate cancer and find out how far the disease has spread. Giving 68Ga-PSMA-11 with PET/CT may help doctors plan better for salvage radiation therapy in participants with recurrent prostate cancer.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-06-27; most recent amendment 2026-05-21.
Status change: Recruiting → Active, Not Recruiting 2020-08-27
Status change: Not Yet Recruiting → Recruiting 2018-09-17
Trial Details
NCT Number NCT03582774
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Prostate Carcinoma
Enrollment 193 participants
Start Date 2018-07-12
Primary Completion 2027-07-12 (estimated)
Study Completion 2028-07-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-26